Abstract

Adeno-associated virus (AAV) has become an increasingly popular viral vector for gene therapy. Currently, there are two approved AAV-based gene therapies, and the number of clinical trials is steadily increasing. As with most viral vector-based therapies, production is labor-intensive and expensive due to the use of adherent cell culture production processes. Consequently, for process intensification, the industry has begun to utilize bioreactors. This article explores the development of a suspension-based AAV upstream process to provide a more efficient and cost-effective bioprocessing solution for large-scale production. The use of template tools for upstream process development will be examined, as will development of the clarification and tangential flow filtration unit operations immediately following harvest.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call